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We aimed to assess whether differences in energy metabolism in fibroblast cell lines derived
from patients with Huntington disease were associated with age at onset independent of the
cytosine-adenine-guanine (CAG) repeat number in the mutant allele.
Methods
For this study, we selected 9 pairs of patients with Huntington disease matched for mutant
CAG repeat size and sex, but with a difference of at least 10 years in age at onset, using the
Leiden Huntington disease database. From skin biopsies, we isolated fibroblasts in which we
(1) quantified the ATP concentration before and after a hydrogen-peroxide challenge and (2)
measured mitochondrial respiration and glycolysis in real time, using the Seahorse XF Extra-
cellular Flux Analyzer XF24.
Results
The ATP concentration in fibroblasts was significantly lower in patients with Huntington
disease with an earlier age at onset, independent of calendar age and disease duration. Maximal
respiration, spare capacity, and respiration dependent on complex II activity, and indices of
mitochondrial respiration were significantly lower in patients with Huntington disease with an
earlier age at onset, again independent of calendar age and disease duration.
Conclusions
A less efficient bioenergetics profile was found in fibroblast cells from patients with Huntington
disease with an earlier age at onset independent of mutant CAG repeat size. Thus, differences in
bioenergetics could explain part of the residual variation in age at onset in Huntington disease.
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Huntington disease, a devastating neurodegenerative disor-
der, is caused by an elongated cytosine-adenine-guanine
(CAG) repeat sequence in exon 1 of the huntingtin gene
(HTT).1–3 The length of the CAG repeat sequence accounts
for 50%–70% of the variation in age at onset, leaving a sub-
stantial amount of unexplained variation, which could be at-
tributed to genetic and environmental modifiers.4,5 In
addition to progressive motor disturbances, neuropsychiatric
symptoms, and cognitive decline, patients with Huntington
disease and premanifest mutation carriers suffer from un-
intended weight loss.6,7 Recently, we demonstrated that this
weight loss was associated with a faster rate of disease pro-
gression independent of CAG repeat number.8 Various evi-
dence indeed indicates that disturbances in energy
metabolism and mitochondrial defects play a role in Hun-
tington disease pathology.9–11 Furthermore, mitochondrial
metabolism was found to be impaired in peripheral tissues of
patients with Huntington disease, including lymphoblastoid
cell lines and skin fibroblasts.12–15 In support of the associa-
tion between mitochondrial defects and Huntington disease
symptomology, Huntington disease characteristics emerged
in humans after accidental exposure to 3-nitropropionic acid
(3-NP), a mitochondrial toxin that selectively inhibits the
activity of mitochondrial complex II.16–19 However, to what
extent differences in energy metabolism are associated with
the onset of Huntington disease symptoms independent of
the CAG repeat number is unknown. Therefore, the aim of
our study was to investigate whether differences in energy
metabolism were present in fibroblast cell lines from patients
with Huntington disease with identical CAG repeat sizes but
a large difference in age at onset.
Methods
Participants
From the Leiden Huntington disease database that contained
data on 356 patients with Huntington disease, we selected 9
pairs of patients with Huntington disease older than 18 years,
matched for sex and CAG repeat length, but with a large
difference in age at onset, as defined by an expert neurologist
(R.A.C.R.) based on motor, psychiatric, and/or cognitive
symptoms. As a cutoff, we used a difference in age at onset of
at least 10 years between each pair of patients. Aside from the
age at onset derived from the date of clinical Huntington
disease, we also noted the age at onset as estimated by the
rater based on patient information and the age at onset of
different Huntington disease symptoms (table 1). Exclusion
criteria were presence of inflammatory diseases, an active in-
fectious disease, and the use of anti-inflammatory or immu-
nosuppressive drugs (e.g., non-steroidal anti-inflammatory
drugs, and corticosteroids) or antioxidants (e.g., vitamin C) in
case temporary cessation of medication use (for about 7 times
the drug’s half-life) was not possible before sampling.
Standard protocol approvals, registrations,
and patient consents
The study protocol was approved by the local ethics com-
mittee, and written informed consent was obtained from all
participants.
Sampling and cell culture
During a regular visit to our outpatient clinic, we obtained
phenotypic data and a small skin sample (i.e., 3 mm diameter)
from the upper thigh of each participant via a punch biopsy.
Fibroblasts from the skin samples were cultured in minimal
essential medium (Gibco #10370-07) supplemented with 15%
heat-inactivated fetal bovine serum (Gibco #10270106), 1%
penicillin-streptomycin (10,000U/mL,Gibco #15140122) and
1% GlutaMAX supplement (Gibco #35050061), and stored in
a humidified incubator at 37°C with 5% CO2. For the experi-
ments described below, the fibroblasts were grown up to
a maximum of 15 passages and harvested by trypsinization with
trypsin-EDTA (0.05%, Gibco #25300054) at 37°C.
ATP concentration under oxidative stress
To assess whether bioenergetics differences in fibroblasts’
response to oxidative stress between the matched pairs were
present, we quantified the ATP concentration in the fibro-
blasts after subjecting them to 0.5 mM H2O2 for 0, 5, 10, and
15 minutes. In solid 96-well plates, we plated 12 replicates per
cell line (i.e., 3 replicates per exposure period) with 30,000
cells in 100 μL regular culturing medium per well. Per plate,
we included 14 blank wells (i.e., containing no cells) to which
different ATP standard concentrations would later be added.
Afterward, we incubated the plate for a minimum of 2 hours in
a humidified incubator at 37°C with 5% CO2 to allow the cells
to attach.
We applied oxidative stress to the fibroblasts by replacing the
regular culturing medium with a medium containing 0.5 mM
H2O2 and 5% fetal bovine serum for the appointed stress
periods.20 To block the effect of H2O2 at the end of this
period, we added catalase from bovine liver (50 U/mL me-
dium, Sigma-Aldrich #C9322-1G)20 and replaced the 0.5 mM
H2O2 medium with 250 μL per well of the regular culturing
medium.
We quantified the ATP concentration of the fibroblasts per well
with the Luminescent ATP detection Assay Kit (Abcam
#ab113849) and added different concentrations of the ATP
standard (i.e., 0, 10, 100, 1,000, 10,000, 100,000, and 1,000,000
nM) provided by the kit to the blank wells. Luminescence was
assessed with Perkin Elmer Multimode Plate Reader, Victor
Glossary
CAG = cytosine-adenine-guanine; ECAR = extracellular acidification rate; OCR = oxygen consumption rate.
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X3. We quantified the ATP concentration per well by creating
an ATP standard curve with a corresponding equation based on
the luminescence per ATP standard. Using this standard curve
equation, we determined the ATP concentration according to
the average luminescence of the 3 wells per time point per cell
line.
Mitochondrial respiration and glycolysis
Using the Seahorse XF Extracellular Flux Analyzer XF24, we
could measure mitochondrial respiration and glycolysis simul-
taneously and in real time in our fibroblast cell lines. Respiration
was measured as the oxygen consumption rate (OCR), and
glycolysis was measured as the extracellular acidification rate
(ECAR). In addition, the Seahorse allowed for the injection of 4
toxins during the experimental run and could monitor their
effects over time. In succession, we injected the following tox-
ins: 1 μMoligomycin (ATP-synthase inhibitor); 1 μMcarbonyl,
cyanide-4-(trifluoromethoxy) phenylhydrazone (or cabonyl
cyanide-p-trifluoromethox-yphenyl-hydrazon [FCCP], oxidative
phosphorylation uncoupler); 1M 3-nitropropionic acid (or
3-NP, complex II inhibitor), and 1 μMantimycin A (complex III
inhibitor). Fibroblasts were plated 1 day in advance of the ex-
periment at 60,000 cells per well in a XF24 cell culture micro-
plate. This density resulted in confluent cultures in which cell
growth was blocked because of contact inhibition, avoiding po-
tential biases because of different growth rates between fibroblast
cell lines.21 On the day of the experiment, the regular fibroblast
medium was removed, and the cells were washed twice with XF
assay medium at 37°C, supplemented with 5 mM glucose and
1mM sodium pyruvate, and themediumwas buffered at pH 7.4.
Subsequently, 675 μL of theXF assaymediumwas added to each
well, and the cells were incubated for 60 minutes in a 37°C
incubator without CO2 to allow the cells to equilibrate to the
new medium.
During the experiment, 4 measurements were taken at base-
line for both OCR and ECAR. Afterward, 3 measurements
were taken after every toxin injection. From these values, we
calculated 6 OCR parameters and 2 ECAR parameters. Basal
respiration was defined as the average OCR values at baseline.


























1 41 F 55.0 8.6 46.4 24.7 46.4 21.7 m
41 F 73.8 2.8 71.1 68.1 m
2 41 M 58.2 4.1 54.1 10.1 50.1 — m, p
41 M 67.4 3.2 64.3 — m
3 42 F 52.9 7.8 45.1 28.2 45.1 26.2 p
42 F 78.9 5.6 73.3 71.3 m
4 42 F 42.3 6.4 35.9 18.0 34.9 14.0 m
42 F 59.8 5.9 53.9 48.9 m, p
5 42 M 43.5 6.6 36.9 23.9 35.9 21.9 p
42 M 61.8 1.0 60.8 57.8 m, p
6 42 M 43.0 20.8 22.3 27.1 20.3 28.1 p
42 M 52.0 2.7 49.3 48.3 m, c
7 45 M 43.5 2.2 41.3 15.2 34.3 12.2 p
45 M 58.1 1.6 56.5 46.5 m
8 46 F 39.3 3.9 35.4 11.6 34.4 9.6 m, p, c
46 F 49.9 2.9 47.0 44.0 c
9 46 M 49.0 16.0 33.0 14.0 33.0 13.0 p, c
46 M 51.9 4.9 47.0 46.0 m
Average, y 54.5 5.9 19.2 18.3
Abbreviations: c = cognitive symptom; CAG = cytosine-adenine-guanine; F = female; M = male; m = motor symptom; p = psychiatric symptom.
a Amedical doctor estimates the time at which the symptoms of the patient started based on the information provided by the patient and the patient’s family.
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The average of the 3 OCR values after oligomycin injection
was defined as the OCR due to proton leak. Maximal res-
piration was calculated by taking the average OCR of the 3
measurements after FCCP injection. The average OCR
value after injection of 3-NP was defined as “respiration
after 3-NP injection,” and the average respiration after
antimycin A injection was defined as “non-mitochondrial
respiration.” From these OCR parameters, another 3
parameters were calculated: respiration dedicated to ATP
production (defined as basal respiration minus proton
leak), spare capacity (defined as maximal respiration minus
basal respiration), and respiration dependent on complex II
activity (defined as maximal respiration minus respiration
after 3-NP injection). Basal glycolysis was defined as the
average ECAR of the 4 baseline ECAR measurements, and
the increase in glycolysis after blocking ATP synthase was
calculated by subtracting the basal glycolysis from the av-
erage ECAR after FCCP injection. To ensure that differ-
ences in the absolute averages were not due to variations in
basal respiration and glycolysis, we also calculated the mi-
tochondrial measurements as percentages of basal respira-
tion and glycolysis.
Statistical analysis
To account for both the correlation within matched pairs, as
well as the correlation due to serial measurements in time
during each trial, we applied generalized linear mixed-effects
models to analyze the results of the bioenergetics experi-
ments. We set the calculated average ATP concentrations
after oxidative stress of every cell line per time point as the
target variable. Because of an exponential association be-
tween the ATP concentrations and time, we used the natural
logarithmic transform of the index variable as the target
variable. Group (i.e., earlier age at onset vs later age at on-
set), disease duration, calendar age at the time of biopsy, and
time of exposure to H2O2 were included as fixed effects.
Furthermore, we included a random intercept for each pa-
tient pair, as well as a random slope for time of exposure to
H2O2, to adequately account for both the matching between
each pair of patients and the correlated measurements on
each individual during the experiments. For mitochondrial
respiration and glycolysis, we analyzed every calculated
functional index separately. For each functional index, we
defined the absolute OCR and ECAR or the relative OCR
and ECAR as the target variables and constructed models as
described above. For all models, we used an unstructured
random effect covariance matrix and robust estimations of
covariance, which result in consistent parameter estimates
even if model assumptions are violated. All models were
checked both graphically and analytically. All tests were
2-tailed, and the threshold for statistical significance (i.e., α)
was set at 0.05. All analyses were performed in SPSS version
23.0 (IBM SPSS Statistics for Windows, IBM Corp).
Data availability
Additional data will be made available at the request of other
investigators.
Results
Differences in age at onset
The age at onset in the 18 selected patients with Huntington
disease ranged between 22 and 73 years, and the average
difference in age at onset between patient pairs was 19.2 years.
The patient pairs had CAG repeat sequences between 41 and
46 repeats, and 5 of the 9 pairs were men. Furthermore, the
symptoms at onset of disease varied per patient between
motor, psychiatric, and cognitive symptoms (table 1).
ATP concentrations were lower in the skin
fibroblasts of patients with Huntington
disease with an earlier age at onset
In all fibroblast cell lines, the ATP concentration decreased
over the time exposed to 0.5 mM H2O2. The decrease was
exponential (figure 1 and figure e-1, links.lww.com/NXG/
A84). Therefore, we used the natural logarithmic transform
of the ATP concentration (lnATP) as the target variable in
the analysis. We found that lnATP was significantly lower in
patients with an earlier age at onset compared with the
matched patients with a later age at onset (figure 1 and table
2). This difference was present at baseline in 7 of the 9
couples and continued to be evident throughout the period
the cells were subjected to oxidative stress in 7 couples
(figure e-1). Because the difference in age at onset as esti-
mated by the rater was missing in couple number 2, causing
the data of this couple to be less reliable (table 1), we per-
formed a sensitivity analysis by excluding these patients.
Exclusion of these patients from the analysis did not mate-
rially alter our results (table 2).
Figure 1 Average ATP concentration in the skin fibroblasts
of patients with Huntington disease exposed to
oxidative stress over time
In all fibroblast cell lines, the average ATP concentration decreased expo-
nentially as the time exposed to oxidative stress increased. At every time
point, the group of patients with an earlier age at onset had a lower ATP
concentration comparedwith the group of patients with a later age at onset.
p < 0.001*** indicates the significant effect of group (i.e., earlier or later age
at onset) on the ATP concentration determined using linear mixed-effects
models. Error bars indicate ±SD.
4 Neurology: Genetics | Volume 4, Number 5 | October 2018 Neurology.org/NG
Mitochondrial indices were lower in the skin
fibroblasts of patients with Huntington
disease with an earlier age at onset
The average OCR and the ECAR per Huntington disease
patient group during the experiment are presented in figure
e-2, links.lww.com/NXG/A84. Neither the absolute mito-
chondrial parameters nor the parameters expressed as per-
centage of basal respiration differed significantly per group
before correction for disease duration and calendar age (figure
e-3). However, after correction, we found the absolute OCR
averages to be significantly different between the 2 groups in 4
of the 8 estimated parameters (table 3). The average maximal
respiration was lower in the group of patients with Hun-
tington disease with an earlier age at onset. All 9 patients with
an earlier age at onset had a lower maximal respiration com-
pared with the matched patients with a later age at onset.
Similarly, in 8 of the 9 couples, the spare capacity was lower in
the earlier age at onset group. Furthermore, the respiration
dedicated to ATP production (in 6 couples) and the respi-
ration dependent on complex II activity (in 8 couples) were
significantly lower in the group of patients with Huntington
disease with an earlier age at onset. The average basal respi-
ration was not markedly different between the 2 groups. Av-
erage OCR as a percentage of the basal respiration differed in
3 parameters between the groups, including maximal respi-
ration (in 8 couples), spare capacity (in 8 couples), and res-
piration dependent on complex II activity (in 9 couples). No
difference in average respiration dedicated to ATP production
was found when this variable was defined as a percentage of
basal respiration. The glycolysis parameters did not differ
between the groups, although the difference in basal glycolysis
showed a trend toward statistical significance in which the
group of patients with Huntington disease with an earlier age
at onset had a lower average basal ECAR. To illustrate these
effects, we plotted the unadjusted values, as well as the pre-
dicted values, calculated using the model estimates after
adjustment for disease duration and calendar age (figure 2A-I,
and figure e-3). The effects did not change after excluding
couple 2 in the sensitivity analysis (table 4).
Of interest, disease duration and calendar age were also signifi-
cantly associated with several indices of mitochondrial bio-
energetics. Longer disease duration was accompanied by lower
absolute values of basal respiration, maximal respiration,
respiration after 3-NP injection, respiration dependent on
complex II activity, and glycolysis after blocking ATP synthase.
Furthermore, patients with a higher calendar age had signifi-
cantly lower levels of maximal respiration, respiration dedicated
to ATP production, spare capacity, respiration dependent on
complex II activity, basal glycolysis, and glycolysis after blocking
ATP synthase. In addition, the parameters maximal respiration,
spare capacity, and respiration dependent on complex II activity
were also significantly lower with a higher calendar age when
expressed as percentages of the basal respiration (table 3).
Discussion
We found lower ATP concentrations in the skin fibroblasts of
patients with Huntington disease with an earlier age at onset
compared with those with a later age at onset, independent of
CAG repeat number, sex, calendar age, and disease duration.
In addition, we demonstrated that the fibroblasts of patients
with Huntington disease with an earlier age at onset exhibited
lower mitochondrial respiration indices, including lower
maximal respiration, spare capacity, and respiration de-
pendent on complex II activity in an absolute sense, as well as
relative to their basal respiration levels. Furthermore, we
found that disease duration and age at biopsy were also sig-
nificantly associated with several parameters of mitochondrial
bioenergetics. Although mitochondrial defects have been ex-
tensively documented before in Huntington disease, to our
knowledge, we are the first to demonstrate that differences in
Table 2 Association between the logarithmic transformof the average ATP concentration and earlier vs later age at onset
in HD
Analysis Fixed effects β-coefficienta SE t p Value 95% CI
All cases Group (earlier) −0.709 0.177 −4.00 <0.001*** −1.063 −0.355
Disease duration 0.016 0.025 0.66 0.511 −0.033 0.066
Calendar age 0.000 0.010 −0.04 0.969 −0.021 0.020
Time −0.102 0.008 −13.01 <0.001*** −0.118 −0.087
Sensitivity analysisb Group (earlier) −0.642 0.255 −2.52 0.015* −1.153 −0.132
Disease duration 0.013 0.027 0.50 0.619 −0.040 0.067
Calendar age 0.000 0.011 0.03 0.978 −0.021 0.021
Time −0.101 0.009 −11.56 <0.001*** −0.119 −0.084
Abbreviation: CI = confidence interval.
*p < 0.05, ***p < 0.001.
a This column indicates the change in logarithmic transform of the ATP concentration.
b The analysis excluding patient pair number 2 (table 1).
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Table 3 Association between the calculatedmitochondrial stress test parameters and age at onset inHuntington disease
Measurement Output Variable β-coefficienta SE t p Value 95% CI
Basal respiration OCR Group (earlier) −4.520 18.249 −0.25 0.808 −43.661 34.621
Disease
duration
−1.799 0.650 0.02 0.015 −3.193 −0.405
Calendar age 0.194 0.566 0.74 0.737 −1.020 1.409
Proton leak OCR Group (earlier) −14.298 11.319 −1.26 0.227 −38.575 9.979
Disease
duration
0.143 0.472 0.30 0.766 −0.869 1.156
Calendar age −0.343 0.435 −0.79 0.443 −1.275 0.589
%OCR Group (earlier) −6.784 8.820 −0.77 0.455 −25.701 12.133
Disease
duration
0.807 0.475 1.70 0.112 −0.213 1.826
Calendar age −0.174 0.378 −0.46 0.652 −0.984 0.636
Maximal respiration OCR Group (earlier) −54.176 17.454 −3.10 0.008** −91.610 −16.741
Disease
duration
−3.317 0.822 −4.04 0.001** −5.080 −1.554
Calendar age −2.118 0.818 −2.59 0.021* −3.872 −0.365
%OCR Group (earlier) −46.730 20.325 −2.30 0.037* −90.321 −3.138
Disease
duration
−0.430 0.930 −0.46 0.651 −2.426 1.565
Calendar age −2.577 0.949 −2.72 0.017* −4.613 −0.542
Respiration after 3-NP injection OCR Group (earlier) −17.226 9.145 −1.88 0.081 −36.839 2.387
Disease
duration
−1.277 0.421 −3.03 0.009** −2.180 −0.374
Calendar age −0.529 0.259 −2.05 0.060 −1.084 0.025
%OCR Group (earlier) −5.133 8.749 −0.59 0.567 −23.898 13.632
Disease
duration
−0.527 0.459 −1.15 0.269 −1.511 0.456
Calendar age −0.453 0.565 −0.80 0.436 −1.664 0.758
Nonmitochondrial respiration OCR Group (earlier) −12.355 9.515 −1.30 0.215 −32.763 8.053
Disease
duration
0.699 0.434 1.61 0.129 −0.231 1.629
Calendar age −0.139 0.386 −0.36 0.723 −0.968 0.689
%OCR Group (earlier) −0.607 8.521 −0.07 0.944 −18.881 17.668
Disease
duration
0.933 0.503 1.85 0.085 −0.146 2.013
Calendar age 0.292 0.344 0.85 0.411 −0.446 1.030
Respiration dedicated to ATP production OCR Group (earlier) −38.106 11.243 −3.39 0.004** −62.219 −13.992
Disease
duration
0.936 0.655 0.1.43 0.175 −0.468 2.341
Calendar age −1.818 0.450 −4.04 0.001** −2.783 −0.852
%OCR Group (earlier) 6.784 8.820 0.46 0.455 −12.133 25.701
Disease
duration
−0.807 0.475 −1.70 0.112 −1.826 0.213
Calendar age 0.174 0.378 0.46 0.652 −0.636 0.984
Continued
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bioenergetics were associated with age at onset among
patients with Huntington disease, and thereby, could be an
important target for future therapeutic interventions.
The fact that the ATP concentration was lower in patients with
Huntington disease with an earlier age at onset suggests that
the production of ATP in the cells of these patients may be
impaired to a greater extent compared with their counterparts
or that the cells of patients with a later age at onset carry
a mechanism that protects their ATP metabolism. The pres-
ence of a potential problem with ATP production was sup-
ported by comparable differences in various indices of
mitochondrial respiration. Maximal respiration and mito-
chondrial spare capacity are measures of the ability of mito-
chondria to react to increased energy demands and are critical
for neuronal survival.22–24 These measures were lower in
patients with an earlier age at onset, suggesting that neurons
in these patients could be more vulnerable to damage and
death, thus causing Huntington disease symptoms to start at
a younger age. Of interest, a previous study showed a correla-
tion between decreased levels of spare capacity and increased
reactive oxygen species and mitochondrial DNA lesions in
mutant Huntington disease striatal immortalized neuronal
cells.15 Respiration dependent on complex II activity was also
Table 3 Association between the calculated mitochondrial stress test parameters and age at onset in Huntington disease
(continued)
Measurement Output Variable β-coefficienta SE t p Value 95% CI
Spare capacity OCR Group (earlier) −50.884 9.894 −5.14 <0.001*** −72.104 −29.663
Disease
duration
−1.482 0.700 −2.12 0.053 −2.984 0.019
Calendar age −2.387 0.685 −3.48 0.004** −3.856 −0.918
%OCR Group (earlier) −46.730 20.325 −2.30 0.037* −90.321 −3.138
Disease
duration
−0.430 0.930 −0.46 0.651 −2.426 1.565
Calendar age −2.577 0.949 −2.72 0.017* −4.613 −0.542
Respiration dependent on complex II
activity
OCR Group (earlier) −36.950 13.397 −2.76 0.015* −65.685 −8.216
Disease
duration
−2.039 0.598 −3.41 0.004** −3.323 −0.756
Calendar age −1.589 0.597 −2.66 0.019* −2.868 −0.309
%OCR Group (earlier) −31.122 12.292 −2.53 0.024* −57.486 −4.759
Disease
duration
−0.737 0.415 −1.78 0.097 −1.627 0.153
Calendar age −1.683 0.520 −3.24 0.006** −2.797 −0.569
Basal glycolysis ECAR Group (earlier) −5.404 2.763 −1.96 0.071 −11.331 0.523
Disease
duration
−0.330 0.193 −1.71 0.110 −0.745 0.085
Calendar age −0.447 0.129 −3.46 0.004** −0.724 −0.170
Glycolysis after blocking ATP-synthase ECAR Group (earlier) 0.614 3.302 0.19 0.855 −6.468 7.697
Disease
duration
−0.643 0.153 −4.20 0.001** −0.971 −0.314
Calendar age −0.187 0.079 −2.38 0.032* −0.356 −0.019
%ECAR Group (earlier) 48.604 25.707 1.891 0.080 −6.532 103.739
Disease
duration
−0.010 2.250 −0.004 0.997 −4.835 4.816
Calendar age 4.988 2.202 2.266 0.040* 0.267 9.710
Abbreviations: CI = confidence interval; ECAR = extracellular acidification rate; %ECAR = ECAR as a percentage of basal ECAR; OCR = oxygen consumption rate;
%OCR = OCR as a percentage of basal OCR.
*p < 0.05, **p < 0.01, ***p < 0.001.
a This column indicates the change in OCR, ECAR, %OCR, or %ECAR.
Neurology.org/NG Neurology: Genetics | Volume 4, Number 5 | October 2018 7
Figure 2 Adjusted estimates of the functional indices calculated from the mitochondrial stress test per age group at
symptom onset in Huntington disease
There was no difference in basal respiration between the 2 groups (A). The absolute mitochondrial respiration dedicated to ATP production was significantly
lower in the group of patients with Huntington disease with an earlier age at onset (B). Both the absolutemaximal respiration and themaximal respiration as
a percentage of the basal respiration were significantly lower in the group of patients with Huntington disease with an earlier age at onset (C and D). The
absolute spare capacity and the spare capacity as a percentage of the basal respiration were significantly lower in the group of patients with Huntington
diseasewith an earlier age at onset (E and F). The absolute respiration dependent on complex II activity and the respiration dependent on complex II activity as
a percentage of the basal respiration were also significantly lower in the group of patients with Huntington disease with an earlier age at onset (G and H). The
basal glycolysis did not differ significantly between the 2 groups (I). Adjusted estimates = values adjusted for disease duration and calendar age at the time of
biopsy. Error bars indicate ±SD. *p-value < 0.05. **p-value < 0.01. ***p-value < 0.001. ECAR = extracellular acidification rate; OCR = oxygen consumption rate.
8 Neurology: Genetics | Volume 4, Number 5 | October 2018 Neurology.org/NG
lower in patients with Huntington disease with an earlier age at
onset. Different studies showed that in postmortem samples of
the striatum and cerebral cortex of patients with Huntington
disease, complex II of the mitochondrial electron transport
chain displayed reduced activity, which was associated with
diminished expression of 2 complex II subunits.25–29 The exact
mechanism as to how the mutated huntingtin protein (HTT)
causes the loss of complex II is unknown. Possible hypotheses
include the direct association of mutant HTT with the mito-
chondrial membrane, causing decreased import of subunits
into the mitochondria, increased degradation, or abnormal
assembly.13,29,30 Furthermore, mutant HTT has been shown
to increase cellular oxidative stress, which was associated with
impaired activity of complex II in a yeast model of Huntington
Table 4 Sensitivity analysis of the association between the mitochondrial stress test parameters and age at onset in
Huntington disease
Measurementa Output Variable β-coefficientb SE t p Value 95% CI
Maximal respiration OCR Group (earlier) −56.810 24.570 −2.31 0.039* −110.343 −3.277
Disease
duration
−2.938 1.079 −2.72 0.018* −5.288 −0.588
Calendar age −2.815 0.568 −4.96 <0.001*** −4.053 −1.577
%OCR Group (earlier) −56.330 24.401 −2.31 0.040* −109.495 −3.164
Disease
duration
0.018 0.965 0.02 0.985 −2.084 2.120
Calendar age −2.903 1.061 −2.74 0.018* −5.215 −0.591
Respiration dedicated to ATP production OCR Group (earlier) −31.600 9.310 −3.39 0.005** −51.884 −11.315
Disease
duration
0.619 0.506 1.22 0.245 −0.483 1.721
Calendar age −1.684 0.396 −4.25 0.001** −2.547 −0.821
%OCR Group (earlier) 15.130 7.065 2.14 0.053 −0.263 30.523
Disease
duration
−1.186 0.328 −3.61 0.004** −1.901 −0.471
Calendar age 0.482 0.312 1.55 0.148 −0.197 1.162
Spare capacity OCR Group (earlier) −56.929 11.504 −4.95 <0.001*** −81.995 −31.863
Disease
duration
−1.066 0.619 −1.72 0.111 −2.414 0.283
Calendar age −2.825 0.556 −5.08 <0.001*** −4.037 −1.613
%OCR Group (earlier) −56.330 24.401 −2.31 0.040* −109.495 −3.164
Disease
duration
0.018 0.965 0.02 0.985 −2.084 2.120
Calendar age −2.903 1.061 −2.74 0.018* −5.215 −0.591
Respiration dependent on complex II
activity
OCR Group (earlier) −39.637 17.613 −2.25 0.044* −78.012 −1.261
Disease
duration
−1.773 0.790 −2.24 0.045* −3.495 −0.051
Calendar age −2.015 0.483 −4.17 0.001** −3.067 −0.962
%OCR Group (earlier) −35.371 14.785 −2.39 0.034* −67.584 −3.157
Disease
duration
−0.522 0.465 −1.12 0.284 −1.535 0.492
Calendar age −1.866 0.559 −3.34 0.006** −3.083 −0.649
Abbreviations: CI = confidence interval; ECAR = extracellular acidification rate; %ECAR = ECAR as a percentage of basal ECAR; OCR = oxygen consumption rate;
%OCR = OCR as a percentage of basal OCR.
*p < 0.05, **p < 0.01, ***p < 0.001.
a Analyses performed with exclusion of couple number 2.
b This column indicates the change in OCR, ECAR, %OCR, or %ECAR.
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disease.31–33 Our results here suggest that the reduced ex-
pression of complex II is more pronounced in patients with an
earlier age at onset independent of CAG repeat length, which
could perhaps be due to a more potent association of mutant
HTT with the mitochondrial membrane or a higher vulner-
ability to oxidative stress.
Candidate studies found that a single nucleotide polymorphism
in PPARGC1A, encoding the mitochondrial regulator peroxi-
some proliferator-activated receptor gamma coactivator-1α
(PGC-1α), affected the age at onset in 3 European Huntington
disease cohorts, suggesting that our findings might have a ge-
netic origin.34,35 Moreover, in striata from patients with Hun-
tington disease and different rodentHuntington diseasemodels,
the expression of PGC-1α mRNA was reduced, and upregu-
lating this expression caused prevention of striatal neuronal at-
rophy, improvement of motor deficits, and protection against
mitochondrial dysfunction and cell death, implying that
PGC-1α expression may modify mutant HTT–induced mito-
chondrial toxicity.36–38 Together with our results, these findings
indicate that differences in PGC-1α expression and the conse-
quential variations in bioenergetics profile may result in addi-
tional variation in age at onset in Huntington disease.
We found that as patients suffered fromHuntington disease for
a longer period of time, several indices of mitochondrial res-
piration were significantly lower, independent of calendar age.
This finding is in line with the fact that Huntington disease
pathogenesis is known to involve mitochondrial deficits.39,40
Therefore, a reasonable derivative is that these mitochondrial
deficits become worse as the disease progresses. Mitochondrial
function is also known to decrease with age.41 In accordance,
we found that as the calendar age of patients increased, several
parameters of mitochondrial function decreased. The aging
process itself is unlikely to have accounted for our main finding
(i.e., a better bioenergetics profile in late-onset patients), given
that patients with a later age at onset were older at the time of
biopsy (table 1).
Our study had several limitations. First, although Huntington
disease is primarily a neurologic disease, we were able to find
differences between patients with Huntington disease with an
early onset and late onset of symptoms in skin fibroblasts. The
fact that we could acquire relevant results in these relatively
easy to obtain cells is intriguing and supports the use of fi-
broblast cell models in the research of neurodegenerative
diseases. However, these cells are not the primary cells of
interest. Therefore, repeating similar experiments in a neuro-
nal cell model, such as striatal neurons derived from induced
pluripotent stem cells, is warranted. Second, establishing the
age at onset in Huntington disease is subjective.42 In order to
achieve additional certainty concerning this age, we noted the
age at Huntington disease diagnosis, as well as the age esti-
mated by the rater, which were analogous in 8 of the 9 cou-
ples. In addition, our results did not change after excluding the
couple in which the rater-estimated age at onset was missing
for 1 patient, illustrating that our results are robust and
reliable. Last, we performed several statistical analyses without
applying a correction for multiple testing, given our relatively
small sample size, as well as the fact that bioenergetics
assessments are highly correlated and, thus, cannot be
regarded as independent. Nevertheless, to obtain results with
a higher level of confidence, future research investigating
similar parameters should include a larger number of patients.
We demonstrated an association between age at onset and the
bioenergetics profile in patients withHuntington disease. Thus,
differences in bioenergetics could explain part of the residual
variation in age at onset among patients with Huntington
disease, whereas therapies aimed at enhancing mitochondrial
function may delay disease onset. However, further research
into the mechanisms mediating the association between bio-
energetics and age at onset are needed to develop novel ther-
apies aimed at delaying symptom onset and disease progression
in Huntington disease.
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